

PRECEPTORSHIP PROGRAMME

Metastatic Bladder and Kidney Cancer

Multidisciplinary management,
standards of care, therapeutic targets
and future perspectives

**ESMO VIRTUAL
PRECEPTORSHIP**

2-3 SEPTEMBER 2020

Co-Chairs

Aristotelis Bamias, Greece

Ravindran Kanesvaran, Singapore

ESMO VIRTUAL PRECEPTORSHIP PROGRAMME METASTATIC BLADDER AND KIDNEY CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

2-3 September 2020

CO-CHAIRS: Aristotelis Bamias, Greece
Ravindran Kanesvaran, Singapore

SPEAKERS: Laurence Albiges, France
Lui Shiong Lee, Singapore
Nye-Thane Ngo, Singapore
Thomas B. Powles, United Kingdom
Tanujaa Rajasekaran, Singapore

LEARNING OBJECTIVES

- To learn about fundamentals of molecular pathology and diagnosis as contributing factors to heterogeneity in bladder and kidney cancer
- To understand essentials in the assessment and multidisciplinary treatment of bladder and kidney cancer
- To learn about advances in treatment and novel targets in bladder and kidney cancer

ACCREDITATION

The programme of this event has been accredited with **6 ESMO-MORA category 1 points**.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org.

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



All timings are to be considered GMT+8

Wednesday, 2 September 2020

15:00-15:05 5'	Opening and welcome	
5'	Welcome from ESMO - Objectives and scientific introduction	Aristotelis Bamias, GR Ravindran Kanesvaran, SG
15:05-15:35 30'	SESSION 1 - Pathology and molecular pathology	Chair/Moderator: Aristotelis Bamias, GR Ravindran Kanesvaran, SG
10'	Bladder cancer	Nye-Thane Ngo, SG
10'	Kidney cancer	Nye-Thane Ngo, SG
10'	Discussion	Faculty
15:35-17:05 90'	SESSION 2 – How to treat metastatic bladder cancer	Chair/Moderator: Ravindran Kanesvaran, SG
15'	1 st line mUC management	Thomas B. Powles, UK
15'	2 nd line and beyond: the art and science of sequencing in mUC	Thomas B. Powles, UK
15'	Discussion	Faculty
45'	Participants clinical case discussion (3x15')	Faculty
17:05-17:20	Break	
17:20-18:20 60'	SESSION 3 – How to treat metastatic renal cell cancer (RCC)	Chair/Moderator: Aristotelis Bamias, GR
10'	Surgery	Lui Shiong Lee, SG
15'	1 st line treatment for clear-cell mRCC	Ravindran Kanesvaran, SG
15'	2 nd line treatment for cc mRCC and sequencing of therapies	Thomas B. Powles, UK
10'	Treatment for non-clear-cell mRCC	Tanujaa Rajasekaran, SG
10'	Discussion	Faculty

Thursday, 3 September 2020

15:00-15:45 45'	SESSION 4 – Debate of the day	Chair/Moderator: Aristotelis Bamias, GR
30'	Should VEGFR TKI + CPI combination be the standard 1 st line systemic therapy for all metastatic RCC patients? YES/NO	Tanujaa Rajasekaran, SG (YES) Laurence Albiges, FR (NO)
15'	Discussion	Faculty

15:45 -16:30 45'	SESSION 5 – Personalized therapy in metastatic bladder cancer and RCC	Chair/Moderator: Ravindran Kanesvaran, SG
15'	Bladder cancer	Aristotelis Bamias, GR
15'	RCC	Laurence Albiges, FR
15'	Discussion	Faculty
16:30-16:40	Break	
16:40-18:20 100'	SESSION 6 - Side effects	Chair/Moderator: Aristotelis Bamias , GR
10'	Chemotherapy	Ravindran Kanesvaran, SG
15'	Tyrosine Kinase Inhibitors and mTOR Inhibitors in RCC	Tanujaa Rajasekaran, SG
15'	Immunotherapy	Laurence Albiges, FR
15'	Discussion	Faculty
45'	Participants clinical case discussion (3x15')	Faculty
18:20-18:25 5'	Conclusion and farewell	Aristotelis Bamias, GR Ravindran Kanesvaran, SG

Note: Each 15-minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion